Rules, risks, and reality: rethinking gene therapy eligibility
Open Access
- 29 January 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 618-619
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?Blood Advances, 2026
- An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemiaBlood Advances, 2025
- Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?Blood Advances, 2025
- Exagamglogene Autotemcel for Severe Sickle Cell DiseaseNew England Journal of Medicine, 2024
- A Review of Gene Therapies for HemoglobinopathiesHemoglobin, 2024
- Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregiversPediatric Blood & Cancer, 2023
- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell DiseaseNew England Journal of Medicine, 2022
- Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell diseaseBlood, 2020
- Perceived Discrimination, Patient Trust, and Adherence to Medical Recommendations Among Persons with Sickle Cell DiseaseJournal of General Internal Medicine, 2014